Insmed Incorporated (LON:0JAV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 19.43B -12.3% |
| Revenue (ttm) | 857.44M +185.8% |
| Net Income | -659.72M |
| EPS | -3.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 857 |
| Open | 122.90 |
| Previous Close | 119.63 |
| Day's Range | 116.20 - 123.71 |
| 52-Week Range | 91.59 - 214.00 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 29, 2026 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Insmed resumed with a Buy at Goldman Sachs
Goldman Sachs resumed coverage of Insmed (INSM) with a Buy rating and $188 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite…
Insmed says FDA grants Priority Review to sNDA for Arikayce
Insmed (INSM) announced that the U.S. FDA has accepted the company’s Supplemental New Drug Application for review of Arikayce for the treatment of Mycobacterium avium complex lung disease as part…
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Mar...
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed I...
Insmed price target lowered to $198 from $212 at Roth Capital
Roth Capital analyst Adam Walsh lowered the firm’s price target on Insmed (INSM) to $198 from $212 and keeps a Buy rating on the shares. The firm has lowered its…
Insmed Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
BRINSUPRI's launch has exceeded expectations, with first-year revenue estimates of $1.25–$1.4 billion and peak sales guidance raised above $7 billion. Expansion into COPD/asthma comorbid populations and international markets, especially Japan, are key growth drivers. The pipeline, including TPIP and gene therapies, is advancing, and AI is deeply integrated across operations.
Insmed Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Peak sales guidance was raised to $14 billion, driven by strong BRINSUPRI and TPIP performance and expanding indications. The BRINSUPRI launch exceeded benchmarks, with rapid patient uptake, high payer approval, and growing market potential. Profitability is expected next year.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed announces five abstracts highlighting data at ERS Congress 2026
Insmed (INSM) Incorporated announced that five abstracts highlighting data from its respiratory portfolio have been accepted for presentation at the European Respiratory Society, ERS, Congress 2026 ta...
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
— New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease— —New Rese...
Insmed to Present at September 2026 Investor Conferences
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Mizuho ups Insmed price target, says share weakness is unwarranted
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Insmed (INSM) to $195 from $192 and keeps an Outperform rating on the shares after Japanese approval of Brinsupri for…
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on August 24, 2026.
Insmed announces Japan’s MHLW approves Brinsupri
Insmed (INSM) announced that Japan’s Ministry of Health, Labour and Welfare has approved Brinsupri, an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and pediatric patient...
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER,...
Insmed price target raised to $195 from $185 at Truist
Truist raised the firm’s price target on Insmed (INSM) to $195 from $185 and keeps a Buy rating on the shares. The firm cites the company’s strong Q2 results, driven…
Insmed price target lowered to $175 from $179 at JPMorgan
JPMorgan lowered the firm’s price target on Insmed (INSM) to $175 from $179 and keeps an Overweight rating on the shares.
Insmed price target raised to $218 from $212 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Insmed (INSM) to $218 from $212 and keeps an Overweight rating on the shares.
Insmed price target raised to $170 from $160 at Evercore ISI
Evercore ISI raised the firm’s price target on Insmed (INSM) to $170 from $160 and keeps an Outperform rating on the shares.
Insmed price target lowered to $205 from $207 at Guggenheim
Guggenheim lowered the firm’s price target on Insmed (INSM) to $205 from $207 and keeps a Buy rating on the shares.
Insmed price target raised to $172 from $166 at UBS
UBS raised the firm’s price target on Insmed (INSM) to $172 from $166 and keeps a Buy rating on the shares. Insmed delivered a strong Q2 beat and raised guidance,…
Insmed price target raised to $169 from $161 at Wells Fargo
Wells Fargo raised the firm’s price target on Insmed (INSM) to $169 from $161 and keeps an Overweight rating on the shares. The firm is impressed with the Brinsupri launch,…
Insmed price target raised to $175 from $160 at Jefferies
Jefferies raised the firm’s price target on Insmed (INSM) to $175 from $160 and keeps a Buy rating on the shares. A “strong” Q2 beat supports the FY26 guidance raise…
